Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

IDEA Collider: Innovation & Asymmetric Learning in Pharma

IDEA Collider: Innovation & Asymmetric Learning in Pharma artwork

Rewriting the Future of Rare Disease: Engineered tRNA and a New Therapeutic Paradigm with Michelle Werner

Feb 18, 202641 minAudio
ShareXLinkedInFacebookWhatsAppEmail

In this episode of IDEA Collider, host Mike Rea sits down with Michelle Werner, CEO of Alltrna, to explore a groundbreaking approach that could transform how we treat thousands of genetic diseases. Michelle shares how engineered transfer RNA (tRNA) technology has the potential to address nonsense mutations - a single class of genetic errors that account for roughly 10% of genetic diseases, affecting millions worldwide. Rather than the traditional “one drug, one disease” model, Alltrna is pursuing a mutation-targeted strategy that could treat multiple diseases with a single therapeutic platform. Episode Timestamps; 00:00 Welcome to Idea Collider: Asymmetric Learning in Pharma 00:19 Meet Michelle Werner: Leading Alltrna’s tRNA Platform 02:09 From Cancer Clinic to Pharma: A Patient-First Career Path 06:18 Big Pharma vs Biotech CEO: Finding Your Authentic Leadership Style 09:37 Vulnerability & Psychological Safety: Building High-Trust Teams 11:46 A Personal Turning Point: Her Son’s Duchenne Diagnosis 17:11 Rare Disease Renegades: A Nonprofit to Accelerate Innovation 18:19 Why Flagship Pioneering: The Ecosystem Behind Alltrna 22:31 tRNA 101: Targeting Stop-Codon Disease Across Thousands of Conditions 28:46 Rethinking Trials, Indications & FDA Pathways for Mutation-First Medicines 33:49 From Preclinical to First-in-Human: Alltrna’s 2026 Milestones 36:49 What Keeps a CEO Up at Night + Final Takeaway: Is This Rare Disease’s Inflection Point? Michelle also reflects on how her personal experience as a parent of a child with a rare condition fuels her commitment to accelerating therapies for patients who currently have few or no options. This episode highlights a pivotal question for the industry: Are rare diseases at the same inflection point oncology experienced two decades ago? Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Michelle Werner; LinkedIn: https://www.linkedin.com/in/michelle-c-werner/ Website: https://www.alltrna.com/ Follow Mike Rea On; Website: https://www.ideapharma.com/ X: https://x.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. ESMO 2026 Preview: Key studies that could fundamentally change the oncology landscape.

    Oct 22, 202642 minAudio

    In this episode of the IDEA Collider podcast, Alex Gray, Chief Medical Officer at SAI & IDEA Pharma, John Barry, Executive Vice President at SAI, and Tom Brockbank, Senior Consultant at IDEA Pharma, look ahead to ESMO...

    Credit the people on this episode

  2. AI-Driven Pharma Market Research: Synthetic Users - with Kwame Ferreira & Rebecca Gould.

    Oct 7, 202641 minAudio

    Welcome back to the IDEA Collider podcast. In this episode, host Rick Ritacco sits down with Kwame Ferreira, Founder of Synthetic Users, and Rebecca Gould, President, Strategic Consulting & Analytics Business Unit at...

    Credit the people on this episode

  3. The Keytruda Blueprint: Alex Gray, David Radwaner, and Tom Brockbank on the IO Revolution: Part II

    Sep 14, 202636 minAudio

    Welcome back to the IDEA Collider podcast. In this second instalment of our future of immuno-oncology series, Alex Gray is joined by colleagues David Radwaner and Tom Brockbank to discuss what lies ahead for cancer...

    Credit the people on this episode

  4. Targeting the Totality of MS: Jason Tardio on Immunic’s Combined Neuroprotective and Anti-Inflammatory Strategy

    Jul 16, 202649 minAudio

    Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Jason Tardio, President and COO of Immunic, to discuss the rapidly evolving landscape of Multiple Sclerosis (MS) treatment. For 30...

    Credit the people on this episode

  5. The Future of Psychedelic Medicine: Clinical Strategy and Scaling Access.

    Jul 1, 202650 minAudio

    Welcome to a special edition of IDEA Collider’s "Deep Medicine" series. In this episode, host Alex Gray sits down with Athina Metaxa, a consultant at IDEA Pharma and psychedelic research expert, to discuss the rapidly...

    Credit the people on this episode